Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Salma H Azam

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Investigation|March 22, 2016
Cancer's got nerve: Schwann cells drive perineural invasionSalma H Azam, Chad V Pecot
Frontiers in Pharmacology|April 20, 2018
Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor MicroenvironmentEmily B Harrison, Salma H Azam, Chad V Pecot
Journal of Visualized Experiments : Jove|March 20, 2018
Incorporating Pericytes into an Endothelial Cell Bead Sprouting AssaySalma H Azam, Mitchell Smith, Vivek Somasundaram, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Isolation Methods of Tumor Endothelial Cells Impact AngiomiR ProfilesLincy Edatt, Gargi Dixit, Salma H Azam, et al.
The Journal of Clinical Investigation|January 6, 2022
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibitionYihsuan S Tsai, Mark G Woodcock, Salma H Azam, et al.
Bio-Protocol|April 15, 2021
Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble DrugsNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
Science Advances|June 30, 2020
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinomaNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
Bio-Protocol|April 15, 2021
Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic AgentsNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNABjoern Papke, Salma H Azam, Anne Y Feng, et al.
The Journal of Clinical Investigation|August 5, 2025
Inverted chimeric RNAi molecules synergistically co-target MYC and KRAS in KRAS-driven cancersYogitha S Chareddy, Hayden P Huggins, Snehasudha S Sahoo, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Investigation|March 22, 2016
Cancer's got nerve: Schwann cells drive perineural invasionSalma H Azam, Chad V Pecot
Frontiers in Pharmacology|April 20, 2018
Targeting Accessories to the Crime: Nanoparticle Nucleic Acid Delivery to the Tumor MicroenvironmentEmily B Harrison, Salma H Azam, Chad V Pecot
Journal of Visualized Experiments : Jove|March 20, 2018
Incorporating Pericytes into an Endothelial Cell Bead Sprouting AssaySalma H Azam, Mitchell Smith, Vivek Somasundaram, et al.
Biorxiv : the Preprint Server for Biology|July 9, 2025
Isolation Methods of Tumor Endothelial Cells Impact AngiomiR ProfilesLincy Edatt, Gargi Dixit, Salma H Azam, et al.
The Journal of Clinical Investigation|January 6, 2022
Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibitionYihsuan S Tsai, Mark G Woodcock, Salma H Azam, et al.
Bio-Protocol|April 15, 2021
Preparation and Characterization of Poly(2-oxazoline) Micelles for the Solubilization and Delivery of Water Insoluble DrugsNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
Science Advances|June 30, 2020
High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinomaNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
Bio-Protocol|April 15, 2021
Preparation of an Orthotopic, Syngeneic Model of Lung Adenocarcinoma and the Testing of the Antitumor Efficacy of Poly(2-oxazoline) Formulation of Chemo-and Immunotherapeutic AgentsNatasha Vinod, Duhyeong Hwang, Salma H Azam, et al.
ACS Pharmacology & Translational Science|April 16, 2021
Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNABjoern Papke, Salma H Azam, Anne Y Feng, et al.
The Journal of Clinical Investigation|August 5, 2025
Inverted chimeric RNAi molecules synergistically co-target MYC and KRAS in KRAS-driven cancersYogitha S Chareddy, Hayden P Huggins, Snehasudha S Sahoo, et al.
Pageof 2